Literature DB >> 1911184

Human tumour-associated NK cells secrete increased amounts of interferon-gamma and interleukin-4.

J Lorenzen1, C E Lewis, D McCracken, E Horak, M Greenall, J O McGee.   

Abstract

Numerous interactions between malignant and stromal/inflammatory cells take place within solid human tumours, which are mediated, in part, by the release of signalling proteins called cytokines. In the present study, we have compared the secretion of two important immunomodulatory cytokines, IFN-gamma and IL-4 by individual, immunophenotyped NK cells freshly isolated from either malignant tumour biopsies, or peripheral blood samples from patients with ductal invasive breast cancer. Due to the marked heterogeneity amongst cells isolated from these clinical samples, we have employed a technique called the reverse haemolytic plaque assay to identify and enumerate cytokine-secreting cells at the single cell level. Our data indicate that NK cells isolated directly from the tumour site secrete more IFN-gamma and IL-4 than NK cells from the blood of the same patients. However, a greater proportion of CD16+ cells from both sources in breast cancer patients secreted IFN-gamma than of those from the blood of healthy donors. We also show that factors secreted by the human breast cell lines, MCF-7 and MDA-231 PN9, were able to mimic the stimulatory influence of the tumour microenvironment on secretory activity of NK cells.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1911184      PMCID: PMC1977624          DOI: 10.1038/bjc.1991.331

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  45 in total

1.  Inhibition of lymphokine-activated killer cell generation by cultured tumor cell lines in vitro.

Authors:  P J Guillou; P C Sedman; C W Ramsden
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

2.  One-signal requirement for interferon-gamma production by human large granular lymphocytes.

Authors:  H A Young; J R Ortaldo
Journal:  J Immunol       Date:  1987-08-01       Impact factor: 5.422

3.  Interferon-gamma upregulates the susceptibility of human neuroblastoma cells to interleukin-2-activated natural killer cells.

Authors:  R Handgretinger; A Kimmig; P Lang; B Daurer; S Kuci; G Bruchelt; J Treuner; D Niethammer
Journal:  Nat Immun Cell Growth Regul       Date:  1989

4.  Induction of human lymphokine-activated killer cells by IFN-alpha and IFN-gamma.

Authors:  T M Ellis; R S McKenzie; P E Simms; B A Helfrich; R I Fisher
Journal:  J Immunol       Date:  1989-12-15       Impact factor: 5.422

5.  Restricted production of interleukin 4 by activated human T cells.

Authors:  D B Lewis; K S Prickett; A Larsen; K Grabstein; M Weaver; C B Wilson
Journal:  Proc Natl Acad Sci U S A       Date:  1988-12       Impact factor: 11.205

6.  Different immune functions of peripheral blood, regional lymph node, and tumor infiltrating lymphocytes in lung cancer patients.

Authors:  H Nakamura; K Ishiguro; T Mori
Journal:  Cancer       Date:  1988-12-15       Impact factor: 6.860

7.  Natural cytotoxicity of human blood lymphocytes and monocytes and their cytotoxic factors: effect of interferon on target cell susceptibility.

Authors:  A Uchida; F Vánky; E Klein
Journal:  J Natl Cancer Inst       Date:  1985-11       Impact factor: 13.506

8.  Elevated expression of the interleukin 4 receptor in carcinoma: a target for immunotherapy?

Authors:  B Al Jabaari; H M Ladyman; M Larché; G B Sivolapenko; A A Epenetos; M A Ritter
Journal:  Br J Cancer       Date:  1989-06       Impact factor: 7.640

9.  Interleukin 6 decreases cell-cell association and increases motility of ductal breast carcinoma cells.

Authors:  I Tamm; I Cardinale; J Krueger; J S Murphy; L T May; P B Sehgal
Journal:  J Exp Med       Date:  1989-11-01       Impact factor: 14.307

10.  Recombinant interleukin 4 suppresses the production of interferon gamma by human mononuclear cells.

Authors:  R Peleman; J Wu; C Fargeas; G Delespesse
Journal:  J Exp Med       Date:  1989-11-01       Impact factor: 14.307

View more
  6 in total

Review 1.  AllergoOncology: the role of IgE-mediated allergy in cancer.

Authors:  E Jensen-Jarolim; G Achatz; M C Turner; S Karagiannis; F Legrand; M Capron; M L Penichet; J A Rodríguez; A G Siccardi; L Vangelista; A B Riemer; H Gould
Journal:  Allergy       Date:  2008-07-26       Impact factor: 13.146

2.  A distinct array of proinflammatory cytokines is expressed in human colon epithelial cells in response to bacterial invasion.

Authors:  H C Jung; L Eckmann; S K Yang; A Panja; J Fierer; E Morzycka-Wroblewska; M F Kagnoff
Journal:  J Clin Invest       Date:  1995-01       Impact factor: 14.808

3.  Neisseria gonorrhoeae epithelial cell interaction leads to the activation of the transcription factors nuclear factor kappaB and activator protein 1 and the induction of inflammatory cytokines.

Authors:  M Naumann; S Wessler; C Bartsch; B Wieland; T F Meyer
Journal:  J Exp Med       Date:  1997-07-21       Impact factor: 14.307

4.  Loss of interleukin 4 receptor-associated molecule gp200-MR6 in human breast cancer: prognostic significance.

Authors:  L Kaklamanis; M I Koukourakis; R Leek; A Giatromanolaki; M Ritter; R Whitehouse; K C Gatter; A L Harris
Journal:  Br J Cancer       Date:  1996-11       Impact factor: 7.640

5.  High-salt diet mediates interplay between NK cells and gut microbiota to induce potent tumor immunity.

Authors:  Zaigham Abbas Rizvi; Rajdeep Dalal; Srikanth Sadhu; Yashwant Kumar; Shakti Kumar; Sonu Kumar Gupta; Manas Ranjan Tripathy; Deepak Kumar Rathore; Amit Awasthi
Journal:  Sci Adv       Date:  2021-09-10       Impact factor: 14.136

6.  IDO Downregulation Induces Sensitivity to Pemetrexed, Gemcitabine, FK866, and Methoxyamine in Human Cancer Cells.

Authors:  Saman Maleki Vareki; Di Chen; Christine Di Cresce; Peter J Ferguson; Rene Figueredo; Macarena Pampillo; Mateusz Rytelewski; Mark Vincent; Weiping Min; Xiufen Zheng; James Koropatnick
Journal:  PLoS One       Date:  2015-11-18       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.